摘要
目的:研究泛Janus激酶(Janus kinase,JAK)抑制剂托法替布(tofacitinib)对转化生长因子-β1(transforming growth factor-beta 1,TGF-β1)诱导的肺成纤维细胞向肌成纤维细胞转化的作用及机制,为临床治疗结缔组织病相关的间质性肺疾病提供理论依据。方法:(1)体外培养人胚胎肺成纤维细胞(human fetal lung fibroblast 1,HFL-1),设立6个组,分别为DMSO空白对照组、TGF-β1诱导组、TGF-β1联合不同浓度托法替布(0.5、1.0、2.0、5.0μmol/L)药物干预实验组。采用CCK-8法检测细胞活力,划痕愈合实验检测细胞迁移能力。(2)采用实时荧光定量PCR(quantitative real-time PCR,RT-PCR)、蛋白免疫印迹实验(Western blotting)检测α-平滑肌肌动蛋白(α-smooth muscle actin,α-SMA)、纤维连接蛋白(fibronectin,FN)、Ⅰ型胶原蛋白(collagenⅠ,COL1)基因及蛋白的表达水平。应用RT-PCR和酶联免疫吸附试验检测各组白细胞介素-6(interleukin-6,IL-6)的基因和细胞培养上清液中的蛋白水平。(3)在不同组的细胞培养基中加入DMSO载体对照,以1.0μmol/L和5.0μmol/L的托法替布预培养30 min,然后加入TGF-β1处理1 h、6 h和24 h。以Western blotting检测Smad2/3、信号传导和转录激活因子3(signal transducer and activator of transcription 3,STAT3)的蛋白磷酸化水平。结果:(1)托法替布抑制TGF-β1诱导的HFL-1细胞活力及迁移能力。(2)与空白对照组相比,TGF-β1诱导组HFL-1的α-SMA、COL1A1和FN1基因表达显著上调(P<0.05)。5.0μmol/L托法替布干预组的α-SMA基因表达与TGF-β1诱导组相比显著下调(P<0.05)。0.5~5.0μmol/L托法替布各干预组与TGF-β1诱导组相比均可抑制FN1基因表达(P<0.05)。各干预组与TGF-β1诱导组相比,COL1A1基因的表达无明显变化。(3)Western blotting结果提示,TGF-β1诱导组细胞α-SMA、FN1蛋白水平较对照组显著增加(P<0.05),COL1A1表达未见明显差异。托法替布不同浓度干预组与TGF-β1诱导组相比,α-SMA蛋白表达均有�
Objective:To investigate the effect of tofacitinib,a pan-Janus kinase(JAK)inhibitor,on transforming growth factor-beta 1(TGF-β1)-induced fibroblast to myofibroblast transition(FMT)and to explore its mechanism.To provide a theoretical basis for the clinical treatment of connective tissue disease-related interstitial lung disease(CTD-ILD).Methods:(1)Human fetal lung fibroblast 1(HFL-1)were cultured in vitro,and 6 groups were established:DMSO blank control group,TGF-β1 induction group,and TGF-β1 with different concentrations of tofacitinib(0.5,1.0,2.0,5.0μmol/L)drug intervention experimental groups.CCK-8 was used to measure the cell viability,and wound-healing assay was performed to measure cell migration ability.After 48 h of combined treatment,quantitative real-time PCR(RT-PCR)and Western blotting were used to detect the gene and protein expression levels ofα-smooth muscle actin(α-SMA),fibronectin(FN),and collagen typeⅠ(COL1).(2)RT-PCR and enzyme-linked immunosorbnent assay(ELISA)were used to detect the interleukin-6(IL-6)gene and protein expression changes,respectively.(3)DMSO carrier controls,1.0μmol/L and 5.0μmol/L tofacitinib were added to the cell culture media of different groups for pre-incubation for 30 min,and then TGF-β1 was added to treat for 1 h,6 h and 24 h.The phosphorylation levels of Smad2/3 and signal transducer and activator of transcription 3(STAT3)protein were detected by Western blotting.Results:(1)Tofacitinib inhibited the viability and migration ability of HFL-1 cells after TGF-β1 induction.(2)The expression ofα-SMA,COL1A1 and FN1 genes of HFL-1 in the TGF-β1-induced groups was significantly up-regulated compared with the blank control group(P<0.05).Compared with the TGF-β1 induction group,α-SMA expression in the 5.0μmol/L tofacitinib intervention group was significantly inhi-bited(P<0.05).Compared with the TGF-β1-induced group,FN1 gene was significantly inhibited in each intervention group at a concentration of 0.5-5.0μmol/L(P<0.05).Compared with the TGF-β1-induced group
作者
何珊
陈炘
程琦
朱灵江
张培玉
童淑婷
薛静
杜燕
HE Shan;CHEN Xin;CHENG Qi;ZHU Lingjiang;ZHANG Peiyu;TONG Shuting;XUE Jing;DU Yan(Department of Rheumatology,the Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,310009,China;Department of Rheumatology,the Affiliated Jinhua Hospital of Zhejiang University School of Medicine,Jinhua,321000,Zhejiang,China)
出处
《北京大学学报（医学版）》
CAS
CSCD
北大核心
2024年第3期505-511,共7页
Journal of Peking University:Health Sciences
基金
国家自然科学基金(82271817)
浙江省自然科学基金(LY22H100004)。
